预约演示
更新于：2025-05-07
Estradiol Valerate
戊酸雌二醇
更新于：2025-05-07
概要
基本信息
非在研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H32O3 |
InChIKeyRSEPBGGWRJCQGY-RBRWEJTLSA-N |
CAS号979-32-8 |
关联
69
项与 戊酸雌二醇 相关的临床试验CTR20250237
戊酸雌二醇片人体生物等效性试验
CTR20241844
评价口服瑞卢戈利片治疗子宫肌瘤相关的大量月经出血有效性和安全性的多中心、随机、双盲、安慰剂对照、平行设计的III期临床研究
CTR20250250
戊酸雌二醇片人体生物等效性试验
100 项与 戊酸雌二醇 相关的临床结果
登录后查看更多信息
100 项与 戊酸雌二醇 相关的转化医学
登录后查看更多信息
100 项与 戊酸雌二醇 相关的专利（医药）
登录后查看更多信息
2,499
项与 戊酸雌二醇 相关的文献（医药）2025-05-01ANALYTICA CHIMICA ACTA
Development of a natural porcine-estrogen-receptor-based pseudo immunoassay for screening of 13 estrogens in milk and studying its recognition mechanism
Article
作者: Cui, Peng Lei ; Jiang, Zu Qiang ; Wang, Jian Ping
BACKGROUND:
There have been some immunoassays reported for screening of the residues of estrogens in milk, but these methods can only determine one drug because of the limited recognition abilities of the used antibodies. Due to the broad specific recognition ability, receptor can be used as "special antibody" to develop pseudo immunoassay. However, there has been no article reporting the use of estrogen receptor for determination of estrogens in foods of animal origin so far. Furthermore, the recognition mechanism of estrogen receptor for estrogens have not been thoroughly studied.
RESULTS:
In this study, a type of magnetic probe based on 17β-estradiol was synthesized that was used to produce the natural porcine estrogen receptor with ovarian as the source tissue. Then its recognition mechanisms for 13 estrogens were studied based on the optimal homological model. Results showed it only interacted with estrogens but did not interact with other steroid hormones. Then it was utilized as a broad specific recognition reagent to develop a direct competitive method on 96-well microplate for detection of the 13 drugs in milk. Due to the utilization of streptavidin-biotin labeled horseradish peroxidase as signal amplification system, the sensitivities for the 13 estrogens (limits of detection 0.007-0.0573 ng/mL) were improved for 33-100 folds in comparison with the use of conventional horseradish peroxidase system (limits of detection 0.31-3.53 ng/mL). This method showed no cross-reactivity with other steroid hormones, consistent with the docking result.
SIGNIFICANCE:
This is the first study reporting the use of magnetic probe to produce natural receptor from animal tissues, and this is also the first study reporting a natural estrogen-receptor-based method for multi-determination of estrogens in food sample. With the guidance of this study, more receptors and related analytical methods for other drugs or small molecules maybe are reported in the future.
2025-04-01European Journal of Obstetrics & Gynecology and Reproductive Biology
Longitudinal changes of automated volumetric breast density with postmenopausal hormone therapy
Article
作者: Kim, Seok Hyun ; Chang, Jung Min ; Kim, Hoon ; Hong, Yun Soo ; Ku, Seung-Yup ; Kim, Sung Woo ; Suh, Chang Suk ; Han, Ji Yeon
OBJECTIVE:
To evaluate how volumetric percent density (VPD) changes longitudinally with postmenopausal hormone therapy (HT).
STUDY DESIGN:
Medical records of 297 women who visited the outpatient clinic in a tertiary medical center between 2011 and 2019 were retrospectively reviewed. Study participants were postmenopausal hormone never-users (n = 103), estrogen therapy (ET) users (n = 95), and estrogen plus progestogen (EPT) users (n = 99). All hormone users were naïve to HT before the study. VPD was measured at least twice over 3 years, and was measured before and after HT in all hormone users. Longitudinal VPD changes were analyzed using a linear mixed effects model adjusted for age and body mass index (BMI) at index mammography.
RESULTS:
The mean age (standard deviation) of study participants at index mammography was 53.0 years (3.3 years). Baseline characteristics, including baseline VPD, were similar across the three groups. After adjustment for age and BMI, the predicted slopes of annual VPD change did not differ among never-users, ET users, and EPT users (-6.8 % (95 % CI -12.1 % to -1.6 %), 0.2 % (95 % CI -4.4 % to 4.8 %), and 0.4 % (95 % CI -5.1 % to 4.3 %), respectively (P = 0.21)). Furthermore, subgroup analyses stratified by estrogen formulation did not demonstrate any difference in the slopes of annual VPD change among never-users, conjugated equine estrogen users, estradiol valerate users, and EPT users (-7.0 %, -1.2 %, 4.9 %, and -0.5 %, respectively; P = 0.27).
CONCLUSION:
The predicted annual VPD change did not differ by HT during 3 years of follow-up. Neither ET nor EPT increased VPD.
2025-04-01JOURNAL OF MOLECULAR STRUCTURE
From biosynthesis to therapeutics: A comprehensive review on varied functions of estrogen and selective estrogen receptor modulators
作者: Sant, Akrati ; Ahmad, Imran ; Bhatia, Sonika ; Gupta, Atul
Estrogens are endogenous hormones vital in many physiol. functions in both sexes.An imbalance in the cumulative estrogen concentration creates many health problems, including cancers, osteoporosis, metabolic disorders, and neurol. diseases.This is often associated with the compensatory treatment of estrogen imbalances.The estradiol derivatives such as estriol (E3), mestranol, ethinyl estradiol (EE), estradiol valerate (EV), etc., per se or mainly in combination with progestogens are clin. applied to mitigate the unsubstantial feminine health.Selective estrogen receptor modulators (SERMs) are another class of therapeutics that emerged as crucial therapeutic agents offering tissue-selective estrogenic and anti-estrogenic effects, thus minimizing the undesirable side effects of steroidal therapeutics.Different classes of SERMs, including triarylethylenes, indoles, naphthalenes, and benzopyrans-based moieties, have revolutionized treatment for estrogen disorders such as osteoporosis, breast cancer, hot flashes, etc., due to their ability to modulate ER often with receptor subtype selectivity.Addnl., a combination of SERMs with Selective Estrogen Enzyme Modulators (SEEMs) particularly Aromatase Inhibitors (AIs) is also popular to tackle the clin. demand for the treatment of estrogen disorders.However, relinquishing undesirable side effects and demand for site-specific efficacy created an impetus for developing newer SERMs.An adequate understanding of estrogens, their biosynthesis, and their cognate receptors, i.e., estrogen receptors (ERs; ER-α & ER-β) is required to design or investigate an effective and safe SERM.This review delves into a discussion on the estrogens and diversified SERMs, their clin. implications in estrogen disorders, the emerging targets, and their importance.This review′s novelty relies on collating significant pieces of information and developing an understanding from the literature that renders the scope to design an effective SERM devoid of undesirable side effects.
100 项与 戊酸雌二醇 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 雌激素缺乏症状 | 中国 | 1983-01-01 | |
| 闭经 | 日本 | 1954-11-01 | |
| 更年期 | 日本 | 1954-11-01 | |
| 痛经 | 日本 | 1954-11-01 | |
| 月经过少 | 日本 | 1954-11-01 | |
| 不孕 | 日本 | 1954-11-01 | |
| 月经过多 | 日本 | 1954-11-01 | |
| 月经紊乱 | 日本 | 1954-11-01 | |
| 子宫不规则出血 | 日本 | 1954-11-01 | |
| 卵巢疾病 | 日本 | 1954-11-01 | |
| 子宫疾病 | 日本 | 1954-11-01 | |
| 低雌激素 | 美国 | 1954-07-15 | |
| 前列腺癌 | 美国 | 1954-07-15 | |
| 血管舒缩症 | 美国 | 1954-07-15 | |
| 外阴和阴道萎缩 | 美国 | 1954-07-15 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 552 | Estrogen valerate pretreatment | 選鏇遞壓夢鬱範顧繭積(製蓋蓋築醖衊鹽廠齋齋) = 醖遞夢憲齋繭網餘蓋鏇 襯衊齋艱醖遞築鹽鹹廠 (鏇壓醖齋鹽淵襯憲衊獵 ) | 不佳 | 2022-04-23 | |
Estrogen valerate (Control group) | 選鏇遞壓夢鬱範顧繭積(製蓋蓋築醖衊鹽廠齋齋) = 遞獵窪網築製鹽鑰鬱鏇 襯衊齋艱醖遞築鹽鹹廠 (鏇壓醖齋鹽淵襯憲衊獵 ) | ||||||
临床1/2期 | - | 23 | Estradiol+Progesterone (African American Women) | 鹹醖繭鹹獵繭壓艱淵膚(膚淵鏇積蓋鑰壓廠選築) = 鏇積繭積繭簾積鏇築艱 淵積鬱齋築壓選積廠鬱 (膚蓋鹽蓋鑰獵廠鹽窪蓋, 13.3) 更多 | - | 2017-04-27 | |
Estradiol+Progesterone (Caucasian Women) | 鹹醖繭鹹獵繭壓艱淵膚(膚淵鏇積蓋鑰壓廠選築) = 憲夢襯鹹鑰衊積艱繭壓 淵積鬱齋築壓選積廠鬱 (膚蓋鹽蓋鑰獵廠鹽窪蓋, 11.6) 更多 | ||||||
临床3期 | 63 | (Estriol) | 衊淵選憲壓繭衊觸糧繭(壓獵選餘夢蓋築顧遞獵) = 醖憲廠積壓選觸膚餘壓 壓積壓淵膚糧製鏇鏇獵 (簾網網蓋獵憲積築願廠, 2.3) 更多 | - | 2014-03-28 | ||
(Estradiol) | 衊淵選憲壓繭衊觸糧繭(壓獵選餘夢蓋築顧遞獵) = 鏇繭淵膚構淵網獵鹽觸 壓積壓淵膚糧製鏇鏇獵 (簾網網蓋獵憲積築願廠, 3.3) 更多 | ||||||
临床3期 | 190 | (Estradiol Valerate/Dienogest (Natazia, Qlaira, BAY86-5027)) | 遞鏇選艱簾製夢範蓋積 = 艱鹽願艱淵壓築齋獵願 壓獵願糧遞願窪膚壓餘 (鹽鹽積醖製鏇觸淵願窪, 餘齋壓鏇壓繭鬱願蓋積 ~ 襯壓艱築憲顧廠壓遞艱) 更多 | - | 2011-06-06 | ||
Placebo (Placebo) | 遞鏇選艱簾製夢範蓋積 = 鹽獵膚壓觸選憲鹹膚膚 壓獵願糧遞願窪膚壓餘 (鹽鹽積醖製鏇觸淵願窪, 廠構遞餘鹽製鹽衊醖範 ~ 鹽遞淵憲範繭願鏇襯繭) 更多 | ||||||
临床3期 | 180 | 築網糧願艱艱網蓋獵衊(衊網艱餘製蓋憲獵壓簾) = 糧窪網築顧鏇遞遞憲膚 顧製醖憲簾繭餘膚積艱 (構淵獵顧齋製膚遞鏇遞 ) 更多 | 积极 | 2011-04-01 | |||
Placebo | 築網糧願艱艱網蓋獵衊(衊網艱餘製蓋憲獵壓簾) = 繭鬱淵獵獵夢構網範鏇 顧製醖憲簾繭餘膚積艱 (構淵獵顧齋製膚遞鏇遞 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用